Related Experiment Video
Updated: Aug 7, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
Epidermal growth factor and serum activate distinct pathways to inhibit the BH3 only protein BAD in prostate
1Department of Biochemistry, Faculty of Medicine, National University of Singapore, Singapore.
Abstract:
A better understanding of pathways involved in survival of prostate cancer cells is the key to develop effective and target-selective therapies. Presence of serum or epidermal growth factor in the culture medium of LNCaP cells decreases apoptosis induced by the inhibition of phosphatidylinositol 3-kinase with LY294002. However, intracellular pathway(s) involved in this survival signaling are not well defined. Here, we investigated the mechanism(s) involved in serum or epidermal growth factor-mediated inhibition of LY294002-induced death in LNCaP cells. Cell death was assessed by the percentage of cells in sub-G1 phase and caspase 3 activity. Phosphorylation status of BAD, ERK1/2 and RSKs were assessed by Western blot. Specific gene expression knock down of BAD, BAX, RSK1 and RSK2 were performed using siRNA transfections. Our results demonstrate that cell death induced by LY294002 is mediated by translocation of BAD and BAX proteins from the cytosol to the mitochondria. Whereas, epidermal growth factor activates a MAPK/ERK/RSK1 module leading to inactivation of BAD via Ser(75) phosphorylation, the presence of serum, on the other hand, induces a nonconducive intracellular environment for mitochondrial translocation of dephosphorylated BAD. Taken together, these results indicate that phosphorylation of BAD or inhibition of its translocation to the mitochondria are critical phosphatidylinositol 3-kinase-independent survival pathways in LNCaP cells.
Insights
Understanding prostate cancer cell survival pathways is crucial for targeted therapies. Epidermal growth factor and serum inhibit cell death by affecting BAD and BAX protein translocation, independent of phosphatidylinositol 3-kinase signaling.
Area of Science:
- Oncology
- Cell Biology
- Molecular Signaling
Background:
- Understanding prostate cancer cell survival mechanisms is key to developing targeted therapies.
- Phosphatidylinositol 3-kinase (PI3K) inhibitors like LY294002 induce apoptosis in LNCaP cells, but this is counteracted by serum or epidermal growth factor (EGF).
- The intracellular pathways mediating this survival signaling remain poorly defined.
Purpose of the Study:
- To investigate the mechanisms by which serum or EGF inhibit LY294002-induced apoptosis in LNCaP prostate cancer cells.
- To elucidate the role of BAD and BAX protein translocation and phosphorylation in PI3K-independent survival pathways.
Main Methods:
- Cell death was quantified by sub-G1 phase analysis and caspase 3 activity assays.
- Protein phosphorylation and translocation were assessed using Western blotting for BAD, ERK1/2, and RSKs.
- Gene knockdown of BAD, BAX, RSK1, and RSK2 was performed via siRNA transfection.
Main Results:
- LY294002-induced cell death involves the mitochondrial translocation of BAD and BAX proteins.
- EGF activates the MAPK/ERK/RSK1 pathway, leading to BAD phosphorylation at Ser75 and its inactivation.
- Serum promotes survival by creating an intracellular environment that inhibits the mitochondrial translocation of dephosphorylated BAD.
Conclusions:
- Phosphorylation of BAD or inhibition of its mitochondrial translocation are critical PI3K-independent survival pathways in LNCaP cells.
- These findings highlight novel therapeutic targets for overcoming resistance to PI3K-targeted therapies in prostate cancer.
Related Concept Videos
Mitogens and the Cell Cycle
TGF - β Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The Intrinsic Apoptotic Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation

